Showing results (41-50 of 90) with videos related to
Sort By:
Pageof 9
Bioorganic & Medicinal Chemistry Letters|April 20, 2005
Design and synthesis of potent pyridazine inhibitors of p38 MAP kinaseNuria Tamayo, Lillian Liao, Martin Goldberg, et al.Journal of Drug Education|September 6, 2011
Polysubstance use patterns in underground rave attenders: a cluster analysisFermín Fernandez-Calderón, Oscar M Lozano, Claudio Vidal, et al.Journal of Pharmaceutical and Biomedical Analysis|February 11, 2015
A single-run liquid chromatography mass spectrometry method to quantify neuroactive kynurenine pathway metabolites in rat plasmaLaura Orsatti, Roberto Speziale, Maria Vittoria Orsale, et al.Journal of Huntington'S Disease|February 5, 2025
Lack of Evidence for Kynurenine Pathway Dysfunction in Huntington's Disease: CSF and Plasma Analyses from the HDClarity StudyVinod Khetarpal, Todd Herbst, Celia Dominguez, et al.Biochemical and Biophysical Research Communications|November 4, 2019
Ultrasensitive quantitative measurement of huntingtin phosphorylation at residue S13Cristina Cariulo, Margherita Verani, Paola Martufi, et al.Journal of Huntington'S Disease|July 27, 2014
Assessment of chloroquine treatment for modulating autophagy flux in brain of WT and HD micePetr Vodicka, Junghyun Lim, Dana T Williams, et al.Plos Currents|February 22, 2014
The PDE1/5 Inhibitor SCH-51866 Does Not Modify Disease Progression in the R6/2 Mouse Model of Huntington's DiseaseVahri Beaumont, Larry Park, Arash Rassoulpour, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 17, 2023
In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using 11C-CHDI-180R PET in a Nonhuman Primate Model of Huntington DiseaseDaniele Bertoglio, Alison R Weiss, William Liguore, et al.Biochimica Et Biophysica Acta. Molecular Basis of Disease|August 20, 2025
Post-translational modifications of huntingtin's N17 region: implications for self-association and membrane bindingMariana Gallo, Raffaele Ingenito, Marco Finotto, et al.Archives of Biochemistry and Biophysics|August 13, 2017
Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1)Alberto Bresciani, Antonino Missineo, Mariana Gallo, et al.Pageof 9